シャドーイング練習: Medium Vessel Occlusion: Should We Thrombectomize? - 動画で英語スピーキングを学ぶ

練習モードを選ぶ

各モードは全画面の練習ルームで開きます。

120 文
文が短すぎたり長すぎる場合は、Editをタップして調整してください。
1
Hello everyone, my name is Puriya Moshaydi.
2
I'm a vascular neurologist and neurointerventionist at Tehran University of Medical Sciences.
3
I'm very honored to be invited on this panel discussing thrombectomies in medium vessel occlusions.
4
Should we still treat them?
5
And my take is we should not.
6
I have no conflict of interest and speaking in front of a group of neurodeterventionists and say that do not do thrombectomy,
7
giving me a feeling that is best depicted in this slide, how I divide roles between myself and Dr. Al -Rahimi.
8
So let's first start with talking what is a medium vessel.
9
So we know what large vessel is.
10
Large vessel are basilar arteries, internal carotides, and the main branch of middle cerebral artery.
11
And anything beyond that is considered middle vessel,
12
medium vessel, including PCAs, ACAs, and MCA branches, M2s.
13
There are some nuances.
14
We know that there is an anatomic variability on how M2s are branching.
15
The main application here is sometimes you have a dominant M2s that you see here.
16
one m2 is bigger than the other one
17
and sometimes you have co -dominant m2s and obviously a non -dominant m2
18
so a dominant m2 is actually a large vessel occlusion as they have been included in other lvo trials
19
and non -dominant or co -dominant m2s are in fact medium vessels
20
and the medium vessel occlusion trials published so far include all the medium vessels but majority are m2s so let's
21
take a step back.
22
When Dawn trials were underway and it was published, I was a resident at UPMC, we often had this discussion with my mentor,
23
Tudor Joven, who would argue astonishing number needed to treat of two for any improvement after thrombectomy,
24
any functional outcome improvement at 90 days may indicate that we own a very effective treatment,
25
but may also show that we are being very over selective in a group of patients,
26
meaning that we are able to exclude any patient with lesser likelihood of benefiting from thrombectomy.
27
And so we usually select patients based on the loss known normal, degree of disability, the location of occlusion, and the infarct volume.
28
And so the next generation of trials, which the MEVO trials belong to them, is starting to testing those boundaries.
29
So going beyond the time limits,
30
the publication by my very good friend Shashva Desai showed that if you select patients that are in the
31
DAWN criteria would be included, except the time of onset, even going as far as 72 hours, they would have the same benefit as patients in DAWN.
32
So they successfully crossed the time limit although it's not within our guidelines yet
33
and then we're all aware of the large core trials uh this is the one by dr saraj
34
that the number needed to treat drop from 2 .1 to 7 .7
35
but they still show the benefit for thrombectomies but
36
so the second line was crossed successfully
37
but are we able to go from large vessel thrombectomy to medium vessel thrombectomy And even before starting the trials, was it expected to help?
38
So let's look at the subgroup analysis of the early time point thrombectomy trials and the Hermes meta -analysis.
39
So I want to draw your attention in the subgroup of M2s, which were included in some of those five trials.
40
the subgroup of M2s actually did not benefit from thrombectomy.
41
And also those that their NIH stress scale was less than 10.
42
So the myelore stroke symptoms.
43
And this is important because actually looking at the patients with medium vessel occlusions,
44
the presenting NIH stress scales is an average three points below large vessel occlusion.
45
So you're dealing with a less disabled group of patients, let's call it.
46
And then looking at the subgroup analysis of late -time window EVT, this is from diffuse tree, the same thing showed up.
47
So the subgroup of patients with milder NISOS scale, again, they did not benefit from thrombectomy.
48
So this is how we entered, um, the the information we have before doing the medium vessel occlusion trials
49
and there were some studies on the PCAs and ACA showing
50
that ACA thrombectomy would not change the outcome they were non -randomized
51
but still I think they're worth mentioning
52
and then there was a observational study on PCA thrombectomies
53
that in fact it showed that thrombectomy we call a higher rate of symptomatic ICH and a worse recovery.
54
So this is how we entered.
55
So I want to use this nice picture from the publication by Goldberg and colleagues.
56
We have two published trials, Distal and Escape MVO and Discount, which is not yet published.
57
Correct me if I'm wrong.
58
This is the baseline studies.
59
So what I want to draw your attention to is
60
that each study was enough powered and And they were trying patients with different time points, less than 12 hours, less than 24 hours, less than 8 hours.
61
And they were also variable and allowed different devices to be used.
62
Some obliged the operator to use the stent retriever, some gave them flexibility.
63
So the results that would come from these trials will have generalizability to different times of onset and different device usage.
64
The outcome, again, this is part of the baseline characteristics.
65
You would see that in all the trials, both discount distal and SCAPE -MEVO,
66
the patients that were included as expected they were presented with mylar stroke symptoms
67
so you are doing a procedure on a patient
68
that is much less disabled remember the the average of patient in dawn were
69
about five or six units higher in an NHSRO scale and then the symptomatic ICH in all the trials
70
were really considerable and discounted with 12 percent in distal was 5 .9 percent
71
and 5 .4 percent in escape mevo
72
and then I want to again compare it with the meta -analysis of large vessel occlusion thrombectomies
73
that the symptomatic ICH were only 4 .4 percent so you are treating a patient
74
treating group of patients with milder symptoms with a more risky procedure.
75
So have this in mind.
76
And then in terms of outcomes, so we have the escape mevo and distal,
77
which showed no benefit in outcome at 90 days.
78
As you see, the confidence interval will cross the value one,
79
and the escape mevo in fact showed a higher rate of 90 days mortality
80
which was significant in interventional group so it shows
81
that we're not only benefiting but we are at some point harming
82
so one word of caution that discount results which were preliminary presented in isc
83
it showed that there was a significant improvement in thrombectomy patients for the MRC score equal less than 2 at 90 days.
84
But this was this annotation at the bottom after multiple imputation of missing data.
85
So I don't know what it means.
86
I don't know what it would turn into when it comes out as a full paper.
87
So we have to look out for it.
88
So we are talking about the thrombectomy in a group of patients or in one patient they are facing.
89
You're doing thrombectomy in a patient which has milder symptoms in a risky procedure.
90
But I want to also take this discussion into a global health level.
91
So this is the picture from MT Glasses study,
92
mission thrombectomy, which shows the access of different countries to thrombectomies.
93
As you can see, even the good countries are colored in green, only about a third of patients eligible for thrombectomy have access to it.
94
The situation for other countries is dismal.
95
Majority of MENA countries have less than 10 % access to thrombectomies.
96
So what I'm feeling that as neurointerventionists, although we have the duty to bring the best for our patient,
97
but it seems that we have a more pressing and urgent challenge, meaning that
98
improving access to thrombectomies for large vessel occlusion you know we are living in a world
99
that the resources are limited
100
so we can invest in finer devices for middle vessel occlusion thrombectomies as we we saw
101
that the thrombectomies in this population is more risky
102
so maybe we can already our devices is not uh prepared for it
103
but we can also invest that time and effort and money in making LVO device thrombectomies more available.
104
And that is the subject of grassroots trials,
105
bringing a stent retriever in with the lesser cost so that it could widen its coverage.
106
It actually came out from the Mission Thrombectomy Initiative.
107
And I think it got approval in India, if I'm not wrong, it got approval in Thailand before it.
108
So, So as an interventionist, when I'm facing the MEVO study,
109
we can talk about like different pieces of information that we have.
110
That for MEVO, we are treating patients with milder symptoms.
111
Our procedure is more risky, causing higher degree of symptomatic ICH, even mortality.
112
We have less successful reperfusion and no proven functional outcome.
113
But I think as a next step, if I have a choice of going after improving the devices
114
and refining trials for smaller vessels or trying to widen the very dismal global coverage for mechanical thrombectomy for LVO,
115
I would definitely choose the second one.
116
So, my answer to doing thrombectomies in medium vessel occlusions is no,
117
then I'm leaving a stage to my very good colleague, Dr. Rohini.
118
This is a picture of Tehran from the hospital that I work with.
119
Hopefully, we can all meet there.
120
And thank you for your attention.

アプリをダウンロード

流暢に話すために必要なすべて

AI発音採点文ごとに採点
IPA練習すべての音をマスター
単語学習自分の単語帳を作る
単語ゲーム遊びながら覚える
FOR YOU

おすすめ動画

このレッスンの語彙とスピーキングのポイント

この動画には、シャドーイング用の文が120文、単語が1578語あります。 音声の長さは12:00です。 話す速さは1分あたり約132語で安定しており、シャドーイングしやすいペースです。 英語の頻出3,000語に含まれる単語は76%だけなので、語彙は難しめです。

この動画の重要語彙

動画に出てくる覚えておきたい単語15語を、発音と意味つきで紹介します。

単語発音意味
vessel 名詞/ˈvɛsəl/船舶
dominant 形容詞/ˈdɑmənənt/支配的
symptom 名詞/ˈsɪm(p)təm/症状, 症候
procedure 名詞/pɹəˈsiː.d͡ʒə/手段, やり方
discount 名詞/ˈdɪskaʊnt/割引, 値引き
dawn 名詞/dɔːn/夜明け, 暁
mild 形容詞/ˈmaɪld/穏やか, 緩やか
risky 形容詞/ˈɹɪski/危険な
publication 名詞/ˌpʌblɪˈkeɪʃ(ə)n/出版, 刊行
select 動詞/sɪˈlɛkt/選ぶ
invest 動詞/ɪnˈvɛst/投入する
functional 形容詞/ˈfʌŋkt͡ʃənəl/機能の, 機能する
colleague 名詞/ˈkɒliːɡ/同僚, 同業者
mortality 名詞/mɔɹˈtælɪti/必滅
artery 名詞/ˈɑɹ.təɹ.i/動脈

動画に出てくる句動詞

単語発音意味
come out 動詞/ˌkʌm ˈaʊt/出る
show up 動詞現れる

この動画の文法

話し手がよく使っている文型を、動画の実際の表現とともに紹介します。

文型動画での表現
受動態 be + 過去分詞 — 誰がするかより、何が起きるかに焦点を当てるbe invited · is considered · have been included
関係詞節 who / which + 節 — 人や物について情報を加えるDiscount, which is · results which were · patient which has

注意したい発音

話し手はI'm, don't, we'reなど、短縮形や弱形を14回使っています。聞こえたとおりの短い形で発音しましょう。

  • 「sh」と「zh」の音: publication /ˌpʌblɪˈkeɪʃ(ə)n/, caution /ˈkɔːʃ(ə)n/, occlusion /əˈkluː.ʒən/, annotation /ˌæn.əˈteɪ.ʃən/, astonish /əˈstɑnɪʃ/
  • 長い単語(アクセントの位置に注意): publication /ˌpʌblɪˈkeɪʃ(ə)n/, successfully /səkˈsɛs.fə.li/, mortality /mɔɹˈtælɪti/, mechanical /məˈkænəkəl/, operator /ˈɑpəˌɹeɪtɚ/

この動画での練習方法

  1. まず声を出さずに動画を最後まで聞き、知らない単語をメモします。
  2. 通常の速度で一文ずつシャドーイングし、話し手のリズムに合うまで繰り返します。
  3. 自分の声を録音して元の音声と比べます。vessel, dominant, symptomなどの単語に特に注意しましょう。

シャドーイングとは?英語上達に効果的な理由

シャドーイング(Shadowing)は、もともとプロの通訳者養成プログラムで開発された言語学習法で、多言語習得者として知られるDr. Alexander Arguelles によって広く普及されました。方法はシンプルですが非常に効果的:ネイティブスピーカーの英語を聞きながら、1〜2秒の遅延で声に出してすぐに繰り返す——まるで「影(shadow)」のように話者を追いかけます。文法ドリルや受動的なリスニングと異なり、シャドーイングは脳と口の筋肉が同時にリアルタイムで英語を処理・再現することを強制します。研究により、発音精度、抑揚、リズム、連音、リスニング力、そして会話の流暢さが大幅に向上することが確認されています。IELTSスピーキング対策や自然な英語コミュニケーションを目指す方に特におすすめです。

シャドーイングのやり方: ステップ別の完全ガイドを読む →